Cluster 0: cypa strong inhibitors inducers cytochrome subfamily family polypeptide medications moderate

Cluster 1: infection requiring systemic active therapy antibiotics antibiotic intravenous treatment days

Cluster 2: transaminase serum aminotransferase glutamic oxaloacetic sgot sgpt upper normal pyruvate

Cluster 3: bilirubin mg dl total syndrome gilberts gilbert serum direct unless

Cluster 4: investigational participated study device participating currently agent weeks therapy dose

Cluster 5: phase ii patients aim prior expansion cohort portion study treatment

Cluster 6: creatinine clearance min ml serum mg dl estimated uln crcl

Cluster 7: consent informed procedures study specific provide written prior signed ability

Cluster 8: metastasis brain leptomeningeal known distant patients symptomatic suspected cns evidence

Cluster 9: expectancy life weeks greater patients estimated years equal investigator year

Cluster 10: women contraception men childbearing potential use adequate unwilling pregnant study

Cluster 11: cardiac significant disease arrhythmia function history impaired arrhythmias requiring uncontrolled

Cluster 12: hiv positive known immunodeficiency virus human infection patients cd aids

Cluster 13: contraceptive use potential effective reproductive method study methods men agreed

Cluster 14: qtc interval qt msec corrected prolongation ecg electrocardiogram prolonged milliseconds

Cluster 15: males females years age older aged time consent old non

Cluster 16: hemoglobin dl transfusion days mmol prior transfusions registration erythropoietin transfused

Cluster 17: hgb hemoglobin dl transfusion achieve intervention acceptable days note use

Cluster 18: hemoglobin dl mmol gm hb mg greater level weeks phase

Cluster 19: platelets mm cells days anc prior transfusion registration obtained plt

Cluster 20: received prior therapy patients treatment previously systemic days study weeks

Cluster 21: heart angina myocardial infarction unstable congestive failure cardiac months uncontrolled

Cluster 22: hepatitis virus immunodeficiency hiv human infection known active hcv hbv

Cluster 23: cancer cell basal squamous adequately skin treated years situ malignancy

Cluster 24: granulocyte colony stimulating csf factor count mm absolute factors macrophage

Cluster 25: surgery prior patients weeks days radiation patient major treatment planned

Cluster 26: breast cancer invasive diagnosis prior patients inflammatory metastatic carcinoma dcis

Cluster 27: pregnancy lactation breastfeeding current test positive women testing time standards

Cluster 28: neutrophil absolute count anc mm cells days registration prior support

Cluster 29: signed informed consent written form dated patient guardian study document

Cluster 30: ecog performance status appendix patients score scale equal adequate patient

Cluster 31: feeding breast pregnant women females pregnancy female patients lactating planning

Cluster 32: samples research provide purposes correlative blood willing tissue mandatory willingness

Cluster 33: corticosteroids inhaled topical steroids systemic prednisone immunosuppressive mg doses daily

Cluster 34: ps ecog performance eastern cooperative oncology group status score scale

Cluster 35: bone marrow function adequate involvement cells blood biopsy patients prior

Cluster 36: organ transplant history allogeneic solid allograft allografts corneal marrow bone

Cluster 37: childbearing potential pregnancy test negative female serum females urine prior

Cluster 38: illness compliance social requirements psychiatric intercurrent situations uncontrolled limit study

Cluster 39: platelets ul plt ml microliter cells days transfusion registration prior

Cluster 40: mcl platelets days initiation performed treatment registration prior transfusion obtained

Cluster 41: bilirubin upper normal limit total uln institutional times gilberts syndrome

Cluster 42: ul platelet count lymphocyte neutrophils transfusion independent days obtained prior

Cluster 43: measurable disease evaluable lesion patients non defined cm lesions criteria

Cluster 44: pregnant women excluded study patients planning currently female females patient

Cluster 45: grade toxicity alopecia toxicities prior therapy related recovered resolved previous

Cluster 46: platelet mm count days cells transfusion prior transfusions obtained independent

Cluster 47: interstitial lung pneumonitis disease history evidence active infectious pulmonary ild

Cluster 48: contraception methods intrauterine barrier device method use condom potential effective

Cluster 49: therapy steroid immunosuppressive form systemic receiving immunodeficiency diagnosis dose days

Cluster 50: therapies prior received number anti patients therapy cancer anticancer treatment

Cluster 51: rituximab containing prior therapy treatment regimen refractory months received chemotherapy

Cluster 52: effects recovered prior toxic therapy acute fully grade chemotherapy radiotherapy

Cluster 53: pressure mmhg blood systolic diastolic hypertension bp uncontrolled controlled antihypertensive

Cluster 54: pd programmed anti death ligand cell lymphocyte ctla antibody cytotoxic

Cluster 55: bleeding diathesis active history disorder disorders gastrointestinal known significant evidence

Cluster 56: hemorrhage intracranial stroke months history enrollment prior hemoptysis study dose

Cluster 57: fraction ejection left ventricular lvef cardiac echocardiogram shortening lower normal

Cluster 58: willingness understand sign ability written document informed consent subjects subject

Cluster 59: aminotransferase ast alt aspartate alanine uln upper normal limit times

Cluster 60: eastern cooperative oncology group ecog performance status karnofsky score scale

Cluster 61: bowel gastrointestinal malabsorption resection vomiting absorption nausea small significantly disease

Cluster 62: pneumonitis organizing fibrosis idiopathic pneumonia induced pulmonary history chest obliterans

Cluster 63: transplant stem cell allogeneic autologous prior hematopoietic months received patients

Cluster 64: inr normalized ratio international time uln prothrombin pt thromboplastin partial

Cluster 65: days prior registration study therapy treatment dose radiotherapy enrollment growth

Cluster 66: study pregnant inform suspect immediately agree contraception woman barrier duration

Cluster 67: histologically confirmed cytologically adenocarcinoma diagnosis prostate metastatic cancer nsclc cell

Cluster 68: compliance psychological safety condition protocol study conditions psychiatric medical procedures

Cluster 69: staff medical regimens conduct history noncompliance compliance study planning non

Cluster 70: concurrent therapy investigational agents chemotherapy cancer treatment use immunotherapy anti

Cluster 71: ct pet tomography scan computed emission positron imaging mri disease

Cluster 72: vaccines live attenuated influenza flu seasonal allowed inactivated intranasal vaccine

Cluster 73: mcl neutrophil absolute count anc days initiation performed treatment registration

Cluster 74: mm longest measured measurable accurately lesion dimension diameter ct recorded

Cluster 75: bacterial fungal viral infection active uncontrolled infections systemic requiring antibiotics

Cluster 76: patients eligible study excluded therapy prior treated treatment receiving receive

Cluster 77: hodgkin lymphoma non nhl cell refractory relapsed classical autologous confirmed

Cluster 78: english read speak speaking able understand write spanish ability language

Cluster 79: imaging resonance magnetic mri ct tomography computed scan disease brain

Cluster 80: inability comply procedures unwillingness follow protocol study swallow requirements pills

Cluster 81: hepatitis positive virus hcv antibody hbv antigen surface infection test

Cluster 82: ctcae grade nci neuropathy hemorrhage version event bleeding diarrhea alopecia

Cluster 83: trial confound best abnormality results interfere participate laboratory duration current

Cluster 84: vascular peripheral aortic disease aneurysm significant arterial repair thrombosis collagen

Cluster 85: organ function adequate marrow defined hematologic end laboratory bone days

Cluster 86: brain metastases known patients treated stable trial excluded clinical evidence

Cluster 87: protein urine ratio mg hour serum light dl proteinuria chain

Cluster 88: illness medical psychiatric interfere condition prevent opinion abnormality potentially likely

Cluster 89: carcinoma cell skin basal squamous situ malignancy years cervix treated

Cluster 90: expecting conceive trial projected screening children father visit breastfeeding duration

Cluster 91: monoclonal antibody reaction hypersensitivity severe history antibodies reactions infusion mab

Cluster 92: half lives shorter whichever investigational prior weeks days drug therapy

Cluster 93: disease progression progressive patients evidence leptomeningeal therapy refractory treatment prior

Cluster 94: participant research study received treatment therapy prior disease receiving investigator

Cluster 95: sarcoma soft tissue ewing oncogene homolog tumor diagnosis confirmed rhabdomyosarcoma

Cluster 96: albumin dl serum mg days initiation treatment performed gm registration

Cluster 97: unable unwilling protocol comply follow requirements study consent patients abide

Cluster 98: live vaccine days attenuated received prior dose study vaccination receipt

Cluster 99: tissue tumor biopsy archival available sample slides obtained fresh paraffin

Cluster 100: leukemia aml promyelocytic acute apl mds myeloid diagnosis myelodysplastic patients

Cluster 101: immunodeficiency hiv virus human known positive infection history antibodies acquired

Cluster 102: platinum based chemotherapy regimen disease progression therapy line prior resistant

Cluster 103: contraindication contrast mri hypersensitivity known drugs allergy concomitant including gadolinium

Cluster 104: surgically childbearing sterile potential abstain heterosexual activity sterilized study subjects

Cluster 105: limits normal institutional bilirubin total upper creatinine serum potassium uln

Cluster 106: chemotherapy prior received cytotoxic patients regimen treatment cancer regimens systemic

Cluster 107: bilirubin uln total direct serum syndrome gilbert gilberts levels subjects

Cluster 108: normal limit upper creatinine uln serum times institutional alt ast

Cluster 109: lactating pregnant women females female patients breastfeeding study excluded subject

Cluster 110: alcohol abuse drug history substance current known dependence active illicit

Cluster 111: risk high intermediate ipss mds prognostic scoring international patients disease

Cluster 112: healing wound fracture ulcer non bone presence major days active

Cluster 113: diagnosed newly cancer malignancy patients years previously disease nonmelanoma residual

Cluster 114: therapy prior anti chemotherapy systemic cancer hormonal treatment patients radiation

Cluster 115: weeks earlier administered adverse events recovered agents prior entering study

Cluster 116: recist measurable disease version criteria defined according lesion evaluable based

Cluster 117: inhibitor prior treatment kinase therapy received parp mek cdk mtor

Cluster 118: radiation therapy prior weeks chemotherapy treatment patients study received palliative

Cluster 119: white wbc blood cell cells ul count mm mcl days

Cluster 120: stage iv iii cancer disease ajcc melanoma ii breast nsclc

Cluster 121: bmi mass index body kg obese overweight greater patients weight

Cluster 122: function adequate liver renal marrow bone kidney defined hematological inadequate

Cluster 123: tumor biopsy primary cm patients biopsies solid accessible size resection

Cluster 124: aptt activated thromboplastin partial ptt anticoagulant intended anticoagulants time pt

Cluster 125: receptor er ihc negative estrogen positive progesterone hybridization fish breast

Cluster 126: tuberculosis tb bacillus active known history previous clinical diagnosis latent

Cluster 127: inclusion criteria apply meet registration cohort patients additional specific protocol

Cluster 128: infections active uncontrolled requiring antibiotics systemic illnesses opportunistic patients medical

Cluster 129: cr remission complete induction response aml leukemia pr patients relapse

Cluster 130: heparin low molecular weight warfarin anticoagulation therapeutic aspirin dose lmwh

Cluster 131: concurrently investigational receiving agents study patients therapy treatment agent using

Cluster 132: glioma world organization grade health glioblastoma diagnosis histologically confirmed iv

Cluster 133: contraception use effective agree potential study childbearing male method female

Cluster 134: drug study dose days administration prior weeks investigational therapy experimental

Cluster 135: ischemic transient thrombosis attack cerebrovascular accident deep months embolism history

Cluster 136: qt long syndrome congenital history family qtc interval msec corrected

Cluster 137: cancer diagnosis lung ovarian small cell primary center patients non

Cluster 138: pembrolizumab excipients hypersensitivity severe known grade epacadostat substance active history

Cluster 139: months survival prior past expected enrollment study history treatment therapy

Cluster 140: pulmonary obstructive disease chronic severe requiring copd antibiotics hospitalization history

Cluster 141: common terminology adverse ctcae events grade criteria version institute national

Cluster 142: hla donor matched leukocyte antigen unrelated drb related typing human

Cluster 143: treatment prior previous study patients weeks therapy allowed dose anti

Cluster 144: consent informed able sign understand willing written form document patient

Cluster 145: fasting glucose mg dl mmol triglycerides cholesterol serum plasma diabetes

Cluster 146: agents investigational receiving patients currently participants study anti eligible cancer

Cluster 147: equal greater years age dl count platelets hemoglobin mm platelet

Cluster 148: inhibitors prior kinase treatment tyrosine therapy mtor patients use pik

Cluster 149: nervous central cns metastases active known untreated disease meningitis lymphoma

Cluster 150: hepatitis active infection known chronic hiv history positive viral patients

Cluster 151: step registration prior randomization days eligibility crossover criteria dl patients

Cluster 152: pneumonitis infectious non history steroids required current evidence active known

Cluster 153: egfr alk mutation tki exon kinase mutations epidermal receptor treatment

Cluster 154: leukemia acute plasma chronic cell lymphoblastic myeloid myelogenous lymphoma cml

Cluster 155: response criteria recist solid evaluation tumors measurable disease version evaluable

Cluster 156: capacity forced predicted dlco carbon monoxide fev expiratory volume diffusing

Cluster 157: test pregnancy negative urine serum positive female hours confirmed study

Cluster 158: laboratory values parameters clinical following abnormalities study places clia range

Cluster 159: fcbp agree contact sexual vasectomy condom latex successful potential lenalidomide

Cluster 160: absorption gastrointestinal gi interfere disease alter oral malabsorption significantly disorders

Cluster 161: diabetes mellitus type uncontrolled controlled poorly ac insulin hbac glucose

Cluster 162: autoimmune disease active history systemic past requiring suspected vitiligo immunosuppressive

Cluster 163: major surgery weeks prior study days recovered drug dose effects

Cluster 164: hamster chinese ovary hypersensitivity recombinant products antibodies known human cell

Cluster 165: stable dose decreasing corticosteroids prior days patients weeks corticosteroid enrollment

Cluster 166: time pt prothrombin thromboplastin ptt partial inr uln normalized ratio

Cluster 167: consent informed written voluntary sign guidelines nature legal accordance patients

Cluster 168: month prior therapy study investigational treatment patients enrollment hemoptysis use

Cluster 169: hormone releasing lhrh luteinizing therapy agonist thyroid androgen orchiectomy gnrh

Cluster 170: investigational agent days treatment study prior weeks received drug receiving

Cluster 171: hypersensitivity known excipients components history component drugs study formulation excipient

Cluster 172: weeks prior radiotherapy therapy chemotherapy study treatment dose nitrosoureas mitomycin

Cluster 173: illness pectoris social situations intercurrent arrhythmia uncontrolled compliance congestive limited

Cluster 174: pugh child class score hepatic impairment cirrhosis liver severe classification

Cluster 175: advanced locally metastatic unresectable disease histologically cancer confirmed solid recurrent

Cluster 176: creatinine calculated clearance min ml serum measured uln crcl mg

Cluster 177: allergy known hypersensitivity components history study excipients formulations drug formulation

Cluster 178: score karnofsky lansky performance years age patients kps ambulatory wheelchair

Cluster 179: bearing child potential pregnancy test women negative pregnant serum female

Cluster 180: retinal rvo occlusion vein history evidence current retinopathy serous risk

Cluster 181: following criteria meet patients treatment disease prior therapy defined progression

Cluster 182: history primary immunodeficiency disease prior known hypertensive pancreatitis leptomeningeal patients

Cluster 183: hepatitis reactive qualitative hbsag rna detected hcv ribonucleic surface acid

Cluster 184: creatinine uln serum times institutional renal days registration obtained prior

Cluster 185: lymph node nodes axillary sentinel cm biopsy dissection disease regional

Cluster 186: significant clinically disease cardiac history uncontrolled pulmonary investigator active ecg

Cluster 187: seizure disorder history patients seizures medication brain requiring uncontrolled controlled

Cluster 188: adjuvant chemotherapy neoadjuvant therapy prior setting months metastatic neo treatment

Cluster 189: hypertension uncontrolled diabetes controlled despite pulmonary poorly history medical hypertensive

Cluster 190: pacemaker metal implanted clips implants mri metallic devices pacemakers aneurysm

Cluster 191: age years time patients consent donor men old lansky women

Cluster 192: liver uln disease metastases chronic cirrhosis alt ast hepatitis patients

Cluster 193: inappropriate make judgment study investigator severe interfere patient entry increase

Cluster 194: donor donors matched unrelated related blood cell infusion lymphocyte haploidentical

Cluster 195: nursing pregnant women female patients females excluded lactating study mothers

Cluster 196: mg dl creatinine serum years age maximum male calcium female

Cluster 197: hepatic function adequate renal marrow bone defined hematological coagulation cardiac

Cluster 198: breastfeeding pregnant women females female patients excluded patient subject study

Cluster 199: return follow institution enrolling willing monitoring phase active mayo study

Cluster 200: mri contrast undergo ct patients unable brain scan imaging contraindications

Cluster 201: filtration glomerular rate min ml gfr creatinine estimated clearance renal

Cluster 202: malignancy active years history concurrent treatment second prior requiring patients

Cluster 203: carcinoma cell squamous small urothelial adenocarcinoma histologically clear histology renal

Cluster 204: alkaline phosphatase uln limit normal upper liver alp times bone

Cluster 205: pelvic radiation prior radiotherapy irradiation previous abdominal therapy history patients

Cluster 206: hematologic function adequate renal hepatic inadequate coagulation liver defined toxicity

Cluster 207: autoimmune requiring psoriasis vitiligo diabetes recur hypothyroidism trigger type mellitus

Cluster 208: msec qtcf interval fridericia qt formula corrected ecg screening correction

Cluster 209: disease inflammatory bowel colitis autoimmune ulcerative history arthritis systemic lupus

Cluster 210: swallow capsules tablets able unable patients inability intact pills ability

Cluster 211: cord spinal compression brain metastases leptomeningeal untreated symptomatic stable disease

Cluster 212: expectancy life months greater estimated investigator opinion patients anticipated predicted

Cluster 213: involvement nervous central cns known active lymphoma leukemia patients malignancy

Cluster 214: creatinine institutional clearance normal levels min ml uln upper calculated

Cluster 215: recovered therapy prior grade note molecule complications targeted administered adequately

Cluster 216: neuropathy grade peripheral sensory pain motor greater existing higher patients

Cluster 217: immediate reaction hypersensitivity idiosyncrasy chemically delayed drugs related dmso excipients

Cluster 218: platelet count mcl days transfusion prior transfusions plt dl ml

Cluster 219: board review irb approved institutional consent informed sign understand written

Cluster 220: cancer skin non melanoma malignancy situ years carcinoma cervix invasive

Cluster 221: infection active uncontrolled patients ongoing antibiotics eligible presence evidence systemic

Cluster 222: composition compounds chemical similar attributed allergic reactions biologic history used

Cluster 223: products hypersensitivity blood known murine investigational tobacco containing study allergy

Cluster 224: contraception dose study agree male method adequate abstinence use starting

Cluster 225: karnofsky performance status kps scale score lansky patients greater ecog

Cluster 226: transaminase aminotransferase serum uln sgpt glutamic sgot alt oxaloacetic alanine

Cluster 227: cll lymphocytic sll leukemia chronic iwcll diagnosis lymphoma transformation treatment

Cluster 228: psa ng ml prostate rising progression value specific antigen prostatectomy

Cluster 229: years older age male female aged patients subjects time consent

Cluster 230: exclusion criteria registration apply cohort treatment specific patients tnbc pre

Cluster 231: myeloma multiple diagnosis relapsed refractory imwg therapy criteria working prior

Cluster 232: interfere results study interpretation condition medical investigator participation opinion evaluation

Cluster 233: oxygen air room pulse oximetry saturation supplemental rest dyspnea pulmonary

Cluster 234: cooperation substance abuse disorders interfere psychiatric requirements trial known study

Cluster 235: rems program revlimid registered mandatory comply willing requirements mitigation able

Cluster 236: myocardial infarction months angina unstable history prior coronary study stroke

Cluster 237: uncontrolled medical severe disease active infection conditions seizures concurrent disorder

Cluster 238: eligibility criteria medi phase cohort ii study cancer meet registration

Cluster 239: altered prohibit understanding mental rendering dementia consent informed status psychiatric

Cluster 240: oral medications able medication inability ability patients absorption gastrointestinal tolerate

Cluster 241: standard therapy care advanced solid metastatic refractory available histologically confirmed

Cluster 242: weight loss months hearing lbs body past pounds unintentional program

Cluster 243: opinion condition investigator medical study subject compromise patient participation safety

Cluster 244: comply visits procedures willing able study scheduled follow protocol ability

Cluster 245: mg equivalent prednisone day dose corticosteroids daily corticosteroid systemic steroids

Cluster 246: hcc hepatocellular diagnosis systemic carcinoma sorafenib prior fibrolamellar confirmed liver

Cluster 247: treated situ cancer adequately carcinoma curatively years curative intent malignancy

Cluster 248: antiretroviral combination hiv immunodeficiency positive ineligible virus human therapy patients

Cluster 249: metformin taking hypersensitivity reason subjects insulin currently known patients doxycycline

Cluster 250: muga fraction echocardiogram acquisition ejection scan gated left ventricular lvef

Cluster 251: abdominal perforation fistula gastrointestinal abscess intra history months obstruction gi

Cluster 252: women pregnancy test childbearing negative potential serum days prior urine

Cluster 253: cns metastases nervous central patients disease stable symptomatic treated brain

Cluster 254: lymphoma cell large follicular diffuse dlbcl mantle zone refractory marginal

Cluster 255: longer whichever half lives investigational drug days study prior treatment

Cluster 256: pd inhibitor ctla prior anti treatment therapy including durvalumab previous

Cluster 257: blasts marrow bone leukemia aml blood mds peripheral refractory patients

Cluster 258: cardiovascular significant disease clinically uncontrolled history including evidence pulmonary condition

Cluster 259: traumatic injury major procedure significant surgical open biopsy days study

Cluster 260: prostate cancer adenocarcinoma prior biopsy therapy diagnosis treatment prostatectomy chemotherapy

Cluster 261: replacement systemic modifying thyroxine pituitary disease autoimmune insulin physiologic adrenal

Cluster 262: surgical procedure resection major prior days study weeks biopsy patients

Cluster 263: syndrome myelodysplastic history poems malabsorption organomegaly endocrinopathy polyneuropathy gilbert changes

Cluster 264: severe infection immunodeficiency disease moderate pneumonia bacteremia hospitalization impairment complications

Cluster 265: metastatic disease evidence patients distant prior chemotherapy therapy recurrent cancer

Cluster 266: provide consent informed written able willing trial assent ability patients

Cluster 267: host graft gvhd versus disease transplant active stem allogeneic acute

Cluster 268: wort st phenytoin carbamazepine phenobarbital cypa rifampin johns inducers rifabutin

Cluster 269: kg body weight area surface bsa cells cd weigh patients

Cluster 270: ms qt interval corrected qtc qtcf fridericia mean correction ecg

Cluster 271: use medications prohibited medication drugs taking current study prior concomitant

Cluster 272: ventricular heart arrhythmias fibrillation uncontrolled history myocardial block infarction failure

Cluster 273: zubrod performance status patients registration days prior step ps karnofsky

Cluster 274: patient study subjects prior diagnosis participants subject clinical known blood

Cluster 275: birth control potential effective use study method agree childbearing women

Cluster 276: start treatment prior study weeks days trial investigational therapy radiotherapy

Cluster 277: hcg chorionic gonadotropin beta human test pregnancy negative women potential

Cluster 278: neck head radiation squamous carcinoma cancer cell prior therapy cavity

Cluster 279: physical examination activity history registration compulsorily detained days prior exam

Cluster 280: immunosuppressive systemic corticosteroids medications therapy treatment chronic use medication agents

Cluster 281: creatinine gault cockcroft clearance min ml formula calculated using equation

Cluster 282: access venous internet computer telephone central placement phone adequate sampling

Cluster 283: bilateral hysterectomy oophorectomy potential consecutive postmenopausal months childbearing tubal undergone

Cluster 284: leukocytes mcl ul mm microliter days registration obtained ml phase

Cluster 285: swallow oral retain able medication ability pills medications orally bowels

Cluster 286: finding metabolic reasonable suspicion contraindicates examination render dysfunction physical giving

Cluster 287: testosterone ng dl castrate serum level nmol levels castration androgen

Cluster 288: mother breastfeeding discontinued pregnant excluded women treated study agents potential

Cluster 289: coagulopathy bleeding diathesis evidence history anticoagulation significant therapeutic absence disorder

Cluster 290: requirements comply able study protocol adhere schedule visit monitoring safety

Cluster 291: anti pd ctla antibody prior therapy received checkpoint targeting agent

Cluster 292: ul neutrophil absolute count anc cells days peripheral registration prior

Cluster 293: hg pressure mm blood systolic hypertension diastolic uncontrolled bp despite

Cluster 294: lipase amylase uln serum pancreatitis radiologic normal clinical pancreatic evidence

Cluster 295: allergic reactions reaction history anaphylactic severe hypersensitivity humanized proteins antibodies

Cluster 296: transplantation allogeneic stem organ cell prior solid autologous hematopoietic marrow

Cluster 297: warfarin anticoagulation vitamin antagonists therapeutic use patients receiving concomitant requires

Cluster 298: pleural ascites effusion effusions pericardial requiring paracentesis drainage clinically thoracentesis

Cluster 299: heart york association new failure class congestive nyha iv iii